Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Nutriband Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Nutriband şirketinin toplam hissedar öz sermayesi $12.5M ve toplam borcu $196.8K olup, bu da borç-öz sermaye oranını 1.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $13.6M ve $1.2M dir.

Anahtar bilgiler

1.6%

Borç/özkaynak oranı

US$196.79k

Borç

Faiz karşılama oranı	n/a
Nakit	US$6.76m
Eşitlik	US$12.46m
Toplam yükümlülükler	US$1.17m
Toplam varlıklar	US$13.63m

Son finansal sağlık güncellemeleri

Recent updates

Is Nutriband (NASDAQ:NTRB) A Risky Investment?

Mar 31

Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?

Sep 13

Nutriband GAAP EPS of -$0.12, revenue of $0.5M

Sep 08

Nutriband opens a new branch in Ecuador with plans to expand into the South American market

Jul 22

Nutriband: Advancing Transdermal Delivery Of Injectable Drugs

Nov 01

Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?

Oct 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NTRB 'nin kısa vadeli varlıkları ( $7.2M ) kısa vadeli yükümlülüklerini ( $1.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: NTRB şirketinin kısa vadeli varlıkları ( $7.2M ) uzun vadeli yükümlülüklerini ( $69.1K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NTRB şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: NTRB 'nin borç/öz sermaye oranı son 5 yılda 5.5% seviyesinden 1.6% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NTRB şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: NTRB serbest nakit akışı her yıl % 31.9 1.6 yıl yetecek nakit akışına sahip olacaktır.

Nutriband Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nutriband Inc. announced delayed annual 10-K filing

Is Nutriband (NASDAQ:NTRB) A Risky Investment?

Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?

Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?

Recent updates

Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology

Nutriband Inc. (NasdaqCM:NTRB) announces an Equity Buyback for $1 million worth of its shares.

Second quarter 2025 earnings released: US$0.15 loss per share (vs US$0.11 loss in 2Q 2024)

Nutriband Inc. Provides Product Development Update for its Lead Product Aversa Fentanyl

Nutriband Inc. Appoints Sergei Glinka to Its Board of Directors

Nutriband Inc. announced delayed annual 10-K filing

Full year 2024 earnings released: US$0.69 loss per share (vs US$0.53 loss in FY 2023)

Nutriband Inc. announced that it expects to receive $8.4 million in funding

Is Nutriband (NASDAQ:NTRB) A Risky Investment?

Nutriband Inc. Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch

Nutriband Inc. Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented At 2024 American Academy of Pain Medicine Annual Meeting

Nutriband Inc. Announces Data on the Incidence of Transdermal Patch Abuse and Accidental Pediatric Exposure Will Be Presented At the 2024 American Academy of Pain Medicine Annual Meeting

New minor risk - Shareholder dilution

Nutriband Inc., Annual General Meeting, Jan 21, 2024

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2023)

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?

Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 2Q 2023)

Nutriband Inc. Launches AI Tape Brand Direct- to Consumer Offerings

New major risk - Share price stability

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.075 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Nutriband Inc. to Officially Launch AI Tape brand in First Quarter 2023

Consensus forecasts updated

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to US$13.29

Nutriband Inc., Annual General Meeting, Dec 09, 2022

Consensus EPS estimates fall by 23%

Second quarter 2023 earnings: Revenues miss analyst expectations

Nutriband GAAP EPS of -$0.12, revenue of $0.5M

Nutriband opens a new branch in Ecuador with plans to expand into the South American market

Nutriband Inc.(NasdaqCM:NTRB) dropped from Russell Microcap Value Index

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$14.00

Nutriband Inc. Announces Board Appointments

Consensus revenue estimates fall by 40%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nutriband: Advancing Transdermal Delivery Of Injectable Drugs

Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?

Price target decreased to US$24.00

Nutriband Inc. Signs Exclusive License Agreement with RAMBAM Med Tech Ltd for its Closed System Transfer Device

Nutriband Inc. (OTCPK:NTRB) completed the acquisition of Transdermal and Health product manufacturing business of Pocono Coated Products LLC for $7.5 million.

Nutriband Inc. (OTCPK:NTRB) agreed to acquire Transdermal and Health product manufacturing business of Pocono Coated Products LLC.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin